BIBLIOGRAPHY
BIBLIOGRAPHY


2. Bhardwaj D K; Bisht M S; Jain R K; Munjal A. Phenolics from the Seeds of Argemone mexicana. Phytochemistry, 1982, Vol 21 (8), 2154-2156

3. Capasso A; Piacente S; Pizza C; DeTommasi N; Jatiya C; Sorrentino L. Isoquinoline Alkaloids from Argemone mexicana Reduce Morphine Withdrawal in Guinea pig Ileum. Planta Medica, 1997, Vol 63(4), 326-328

4. CCRAS. Pharmacological investigations of certain medicinal plants and compound formulations used in Ayurveda and Siddha; Publisher, New Delhi, pp. 22-25, (1996)


15. Hart C., Modern Drug Discovery, 20-31 (March/ April 1999)


17. Jablonska S; Chowaniec O; Beutner E H; Maciejowska E; Jarzabek-Chorzelska M; Rzesz G. Stripping of the Stratum Corneum in Patients with Psoriasis: Production of prepinpoint papules and Psoriatic lesions, 1982, Vol 118(9), 652-657


20. Mahto S B; Sahu N P; Narayanaswamy A; Chakroborty R N; Chakroborty D. Structure of Fatty Acids from the Oil of Argemone mexicana. Journal of Indian Chem Society, 1975, Vol 52 (7), 626-628


27. Reich K; Heine A; Hugo S; Blaschke V; Middel P; Kaser A; Tilg H; B S; Gutgesell C; Neumann C. Engagement of the Fc epsilon RI Stimulates the Production of Langerhans Cell-Like Dendritic Cells. Journal of Immunology, Vol 167 (11), 6321-6329.


32. Saleh M A; Abdel R; Fauzia H; Ibrahim N A; Taha N M. Isolation and Structure Determination of a New Nematicidal Triglyceride from Argemone mexicana. Journal of Chemical Ecology, 1987, Vol 13(6), 1361-1370


36. Shivrajan, V V; Balachandran I. Ayurvedic Drugs and their Plant Sources, Published by Oxford and IBH Publication Co. Pvt. Ltd, 1994, 460-462


39. Sukumar D; Nambi R; Arivudai S N. Studies on the leaves of Argemone mexicana. Fitoterapia, 1984, Vol 55(6), 352-353


43. Wealth of India. Vol 1A, PID; CSIR, 1985, 415 417
# ANNEXURE-1

## LIST OF TABLES

<table>
<thead>
<tr>
<th>TABLE NO</th>
<th>DESCRIPTION</th>
<th>PAGE NO.</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Summary of Mortality Data (28 days Repeated dose Toxicity in Rats)</td>
<td>59</td>
</tr>
<tr>
<td>2</td>
<td>Summary of Clinical Findings</td>
<td>59</td>
</tr>
<tr>
<td>3</td>
<td>Group Mean Body Weights</td>
<td>60</td>
</tr>
<tr>
<td>4</td>
<td>Group Mean Absolute and Percent Body Weight Gain Data</td>
<td>62</td>
</tr>
<tr>
<td>5</td>
<td>Group Mean Feed Consumption</td>
<td>64</td>
</tr>
<tr>
<td>6</td>
<td>Group Mean Absolute and Relative Organ Weights</td>
<td>66</td>
</tr>
<tr>
<td>7</td>
<td>Group Mean Hematology Data</td>
<td>68</td>
</tr>
<tr>
<td>8</td>
<td>Group Mean Differential Leukocyte Count</td>
<td>70</td>
</tr>
<tr>
<td>9</td>
<td>Group Mean Clinical Biochemistry Data</td>
<td>72</td>
</tr>
<tr>
<td>10</td>
<td>Summary of Gross Pathological Findings</td>
<td>74</td>
</tr>
<tr>
<td>10 A</td>
<td>Percent Incidence of Gross Pathological Findings</td>
<td>75</td>
</tr>
<tr>
<td>11</td>
<td>Summary of Histopathological Findings</td>
<td>76</td>
</tr>
<tr>
<td>11 A</td>
<td>Percent Incidence of Histopathological Findings</td>
<td>77</td>
</tr>
<tr>
<td>12</td>
<td>Summary of Mortality Data (180 days Repeated dose Toxicity in Rats)</td>
<td>84</td>
</tr>
<tr>
<td>13</td>
<td>Summary of Clinical Findings</td>
<td>85</td>
</tr>
<tr>
<td>14</td>
<td>Group Mean Body Weights</td>
<td>86</td>
</tr>
<tr>
<td>15</td>
<td>Group Mean Absolute and Percent Body Weight Gain Data</td>
<td>96</td>
</tr>
<tr>
<td>16</td>
<td>Group Mean Feed Consumption</td>
<td>108</td>
</tr>
<tr>
<td>17</td>
<td>Group Mean Absolute and Relative Organ Weights</td>
<td>120</td>
</tr>
<tr>
<td>18</td>
<td>Group Mean Hematology Data (Interim)</td>
<td>122</td>
</tr>
<tr>
<td>18 A</td>
<td>Group Mean Hematology Data (Terminal)</td>
<td>124</td>
</tr>
<tr>
<td>19</td>
<td>Group Mean Differential Leukocyte Count (Interim)</td>
<td>126</td>
</tr>
<tr>
<td>19 A</td>
<td>Group Mean Differential Leukocyte Count (Terminal)</td>
<td>128</td>
</tr>
<tr>
<td>20</td>
<td>Group Mean Clinical Biochemistry Data (Interim)</td>
<td>130</td>
</tr>
<tr>
<td>20 A</td>
<td>Group Mean Clinical Biochemistry Data (Terminal)</td>
<td>132</td>
</tr>
<tr>
<td>21</td>
<td>Summary of Gross Pathological Findings</td>
<td>134</td>
</tr>
<tr>
<td>21 A</td>
<td>Percent Incidence of Gross Pathological Findings</td>
<td>135</td>
</tr>
</tbody>
</table>
ANNEXURE-1 CONTD.

22 Summary of Histopathological Findings

22 A Percent Incidence of Histopathological Findings

23 Clinical Signs Grading of Skin Reactions (Dermal Irritation Test)

24 Clinical Signs Grading of Ocular Reactions (Eye Irritation Test)

25 Group Mean Mitotic Index and Chromosomal Aberration (Phase-1)

26 Group Mean Mitotic Index and Chromosomal Aberration (Phase-2)

27 Individual Culture Mitotic Index and Chromosomal Aberration (Phase-1)

28 Individual Culture Mitotic Index and Chromosomal Aberration (Phase-2)

29 Group Mean Body Weights (Micronucleus Test)

30 Group Mean Erythrocyte Count, Ratio and Micronucleated Poly. Erythrocytes

31 Group Mean Body Weights (Phototoxicity Test)

32 Mean One Hour Post Irradiation Erythema and Oedema Score

33 Mean Twenty Four Hour Post Irradiation Erythema and Oedema Score

34 Mean Percent Ear Thickness - Challenge Phase (Mouse Ear Swelling Test)

35 Mean Percent Ear Thickness - Re Challenge Phase

36 Mean Percent Ear Swelling- Challenge Phase

37 Mean Percent Ear Swelling- Re Challenge Phase

38 Mean Body Weights (Mouse Ear Swelling Test)

39 Dose Proportionality of $E_{max}$ in Rats (Oral Route)

40 Dose Proportionality of $AUC_{0-24}$ in Rats (Oral Route)

41 Percent Change in IL-10 induction in Rats @ 75 mg/kg Oral Dose in Rats

42 Percent Change in IL-10 induction in Rats @ 150 mg/kg Oral Dose in Rats

43 Percent Change in IL-10 induction in Rats @ 300 mg/kg Oral Dose in Rats

44 Summary of Pharmacokinetic Parameters Derived from Percent Change

45 Dose Proportionality of $E_{max}$ in Rats (Intravenous Route)

46 Dose Proportionality of $AUC_{0-24}$ in Rats (Intravenous Route)

47 Percent Change in IL-10 induction in Rats @ 25 mg/kg i.v. Dose in Rats

48 Percent Change in IL-10 induction in Rats @ 50 mg/kg i.v. Dose in Rats

49 Percent Change in IL-10 induction in Rats @ 75 mg/kg i.v. Dose in Rats

50 Summary of Pharmacokinetic Parameters Derived from Percent Change